Latest Production Development News

Biotron Limited has met the first milestone in its Sedarex acquisition by securing pivotal regulatory feedback from the European Medicines Agency, charting a clearer path for its next-generation anaesthetic SedRx.

TZ Limited has completed a modest entitlement offer at 3 cents per share, raising approximately $121,000, but a significant shortfall of over 81 million shares remains unallocated. The company plans to place these shortfall shares within three months or let them lapse.

MyEco Group has finalised its operational overhaul, consolidating manufacturing in China and cutting fixed costs to sharpen its focus on sustainable packaging growth.

Mesoblast Limited’s Ryoncil® posted US$36 million in Q4 revenue, driving a full-year total of US$115 million, exceeding initial forecasts. The FDA-approved stem cell therapy for pediatric graft-versus-host disease shows robust uptake across US pediatric centres.

8common Limited posted positive EBITDA and net profit before tax in Q4 FY26, secured a major multi-year contract with the Australian Taxation Office, and fully repaid its loan facility.

ClearVue Technologies has earned three international certifications for its Gen 3 Vision Glass, confirming its photovoltaic performance, safety, and durability across multiple product variants.

Spenda Limited has completed the retail tranche of its $8.545 million entitlement offer, raising $1.15 million at $0.004 per share, with major shareholder Capricorn Society increasing its holding to nearly 20%.

BCAL Diagnostics has acquired a 10.2% stake in Genetic Signatures for $1.39 million, aiming to merge early cancer detection with infectious disease diagnostics and expand its international footprint.

HALO Technologies launches a convertible notes offer aiming to raise up to A$6.75 million, backing platform upgrades and expansion across Asia-Pacific and adviser networks.

Spenda Limited's SPXOB securities have been suspended from trading by the ASX due to non-compliance with listing requirements. The suspension affects only this security class, leaving other Spenda securities unaffected.

Echo IQ has locked in a pivotal exclusive data licensing deal with Advara HeartCare, gaining access to as many as one million de-identified echocardiography studies, a move set to turbocharge its cardiovascular AI development.

Echo IQ has raised approximately A$110 million through a heavily supported institutional placement to fund its US commercial rollout and speed up development of its AI-driven cardiovascular diagnostics.